Results 1 to 10 of about 35,667 (187)
Journal of Lipid Research, 2012 PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) is a crucial protein in LDL cholesterol (LDL-C) metabolism by virtue of its pivotal role in the degradation of the LDL receptor.
Gilles Lambert +4 more
doaj +4 more sources
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents [PDF]
Lipids in Health and Disease, 2011 Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) has been identified as a key regulator of serum LDL-cholesterol (LDL-C) levels.
Troutt Jason S +2 more
doaj +3 more sources
PCSK9 antagonists and inflammation [PDF]
Atherosclerosis, 2018 Corsini, Alberto +3 more
core +5 more sources
PCSK9 Gene Polymorphisms Associated With the Risk of Myocardial Infarction in Iranian Patients [PDF]
International Journal of Basic Science in Medicine, 2021 Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulatory protein in lipid metabolism and a candidate gene in the etiology of cardiovascular diseases.
Farshad Namordizadeh, Mahboobeh Nasiri
doaj +1 more source
Cell, 2016 Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative
Pradeep, Natarajan, Sekar, Kathiresan
openaire +3 more sources
PCSK9 is not secreted from mature differentiated intestinal cells
Journal of Lipid Research, 2021 Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes lysosomal degradation of the LDL receptor and is a key regulator of cholesterol metabolism. After the liver, the small intestine is the second organ that highly expresses PCSK9.
Moreau François +17 more
doaj +1 more source
Vaccines, 2022 Administration of PCSK9-specific monoclonal antibodies, as well as peptide-based PCSK9 vaccines, can lower plasma LDL cholesterol by blocking PCSK9. However, these treatments also cause an increase in plasma PCSK9 levels, presumably due to the formation ...
Louise Goksøyr +8 more
doaj +1 more source
Journal of Lipid Research, 2022 Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) regulates the cell-surface localization of LDL receptors in hepatocytes and is associated with LDL and lipoprotein(a) [Lp(a)] uptake, reducing blood concentrations.
Ioannis Dafnis +5 more
doaj +1 more source
Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function. [PDF]
PLoS ONE, 2015 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a soluble protein that directs membrane-bound receptors to lysosomes for degradation. In the most studied example of this, PCSK9 binding leads to the degradation of low density lipoprotein receptor
Rachel M DeVay +3 more
doaj +1 more source
Archives of Medical Science, 2021 Introduction The aim of the study was to study a nanoliposomal anti-PCSK9 vaccine as a novel approach for cholesterol lowering via PCSK9 inhibition. Material and methods An immunogenic peptide construct termed immunogenic fused PCSK9-tetanus (IFPT) was ...
Amir Abbas Momtazi-Borojeni +4 more
doaj +1 more source